eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Review paper

The efficacy of mometasone furoate for children with asthma: a meta-analysis of randomized controlled trials

Yanling Song
1
,
Kaiyu Pan
2
,
Yuyan Chen
1
,
Xiaoming Wang
1
,
Jun Tian
2

1.
Department of Paediatrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
2.
Department of Paediatrics, The First People’s Hospital of Xiaoshan, Hangzhou, Zhejiang Province, China
Adv Dermatol Allergol 2021; XXXVIII (5): 740-745
Online publish date: 2020/02/25
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The influence of mometasone furoate for paediatric asthma remains controversial.

Aim
We conducted a systematic review and meta-analysis to explore the efficacy and safety of mometasone furoate for paediatric asthma.

Material and methods
We have searched PubMed, Embase, Web of science, EBSCO, and Cochrane library databases through October 2019 for randomized controlled trials assessing the effect of mometasone furoate versus placebo for paediatric asthma. This meta-analysis was performed using the random-effects model.

Results
Four RCTs were included in the meta-analysis. Overall, as compared to placebo for paediatric asthma, mometasone furoate is associated with substantially increased predicted forced expiratory volume in 1 s (FEV1) (mean difference (MD) = 7.53; 95% CI: 7.02–8.04; p < 0.00001), FEV1 (MD = 0.11; 95% CI: 0.10–0.12; p < 0.00001), and morning peak expiratory flow (AM PEF) (MD = 17.70; 95% CI: 9.91–25.49; p < 0.00001), but demonstrates no obvious effect on pharyngitis (RR = 0.96; 95% CI: 0.59–1.58; p = 0.89), upper respiratory tract infections (RR = 0.73; 95% CI: 0.50–1.05; p = 0.09), or adverse events (RR = 1.05; 95% CI: 0.84–1.31; p = 0.69).

Conclusions
Mometasone furoate may be effective and safe for paediatric asthma.

keywords:

mometasone furoate, paediatric asthma, forced expiratory volume in 1 s, randomized controlled trials

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.